Figure 3: *In vivo* Effect on Blood Glucose with Crosslinked PDA-PVAm Copolymers after 4 Weeks of Treatment



Figure 4: *In vivo* Effect on HbA_{1C} with Crosslinked PDA-PVAm Copolymers after 4 Weeks of Treatment



A = vehicle control; B = sevelamer; C = linagliptin; D = Example 1- 1- 4; E = Example 1- 1- 3; F = Example 1- 1- 1; G = sevelamer + linagliptin; H = Example 1- 1- 3 + linagliptin

Figure 5: *In vivo* Effect on Blood Glucose with Crosslinked PDA-PAA Copolymers



Figure 6: *In vivo* Effect on HbA1c with Crosslinked PDA-PAA Copolymers



Figure 7: *In vivo* Effect on Liver Weight with Crosslinked PDA-PAA Copolymers



Figure 8: *In vivo* Effect on Liver Triglycerides with Crosslinked PDA-PAA Copolymers



Figure 9: *In vivo* Effect on Blood Glucose Profile with Crosslinked PDA-PVAm and PDA-PAA Copolymers



Figure 10: *In vivo* Effect on Blood Glucose of KKAy mice treated with Crosslinked PDA-PAA Copolymer after 7 Weeks of Treatment



Figure 11: *In vivo* Effect on HbA1c of KKAy mice treated with Crosslinked PDA-PAA Copolymer after 7 Weeks of Treatment

